SP 13
Update on chimeric antigen receptor – T cells (CAR-T) CD19 therapy: the Sheba experience
Arnon Nagler
Lido
2546
Vezesque se leu este artigo
1176
Total PDF
1370
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 6 | 20 | 8 | 28 |
| 2025 5 | 60 | 10 | 70 |
| 2025 4 | 52 | 16 | 68 |
| 2025 3 | 54 | 13 | 67 |
| 2025 2 | 45 | 26 | 71 |
| 2025 1 | 36 | 17 | 53 |
| 2024 12 | 32 | 16 | 48 |
| 2024 11 | 56 | 19 | 75 |
| 2024 10 | 45 | 22 | 67 |
| 2024 9 | 57 | 18 | 75 |
| 2024 8 | 38 | 24 | 62 |
| 2024 7 | 27 | 20 | 47 |
| 2024 6 | 43 | 25 | 68 |
| 2024 5 | 31 | 21 | 52 |
| 2024 4 | 40 | 20 | 60 |
| 2024 3 | 29 | 23 | 52 |
| 2024 2 | 21 | 22 | 43 |
| 2024 1 | 21 | 25 | 46 |
| 2023 12 | 17 | 16 | 33 |
| 2023 11 | 30 | 31 | 61 |
| 2023 10 | 16 | 28 | 44 |
| 2023 9 | 21 | 35 | 56 |
| 2023 8 | 11 | 14 | 25 |
| 2023 7 | 24 | 10 | 34 |
| 2023 6 | 20 | 19 | 39 |
| 2023 5 | 22 | 16 | 38 |
| 2023 4 | 9 | 2 | 11 |
| 2023 3 | 20 | 21 | 41 |
| 2023 2 | 14 | 17 | 31 |
| 2023 1 | 16 | 4 | 20 |
| 2022 12 | 11 | 15 | 26 |
| 2022 11 | 15 | 16 | 31 |
| 2022 10 | 16 | 21 | 37 |
| 2022 9 | 19 | 22 | 41 |
| 2022 8 | 18 | 17 | 35 |
| 2022 7 | 15 | 25 | 40 |
| 2022 6 | 14 | 28 | 42 |
| 2022 5 | 11 | 20 | 31 |
| 2022 4 | 14 | 26 | 40 |
| 2022 3 | 13 | 13 | 26 |
| 2022 2 | 13 | 19 | 32 |
| 2021 1 | 8 | 11 | 19 |
| 2021 12 | 14 | 22 | 36 |
| 2021 11 | 14 | 23 | 37 |
| 2021 10 | 16 | 37 | 53 |
| 2021 9 | 21 | 32 | 53 |
| 2021 8 | 23 | 35 | 58 |
| 2021 7 | 36 | 26 | 62 |
| 2021 6 | 30 | 37 | 67 |
| 2021 5 | 26 | 42 | 68 |
| 2021 4 | 17 | 25 | 42 |
| 2021 3 | 29 | 36 | 65 |
| 2021 2 | 14 | 19 | 33 |
| 2020 1 | 15 | 21 | 36 |
| 2020 12 | 15 | 19 | 34 |
| 2020 11 | 6 | 11 | 17 |
Mostrar tudo
